Blossom Health, a telepsychiatry startup from New York founded in 2024, has secured $20 million in seed and Series A funding to enhance an AI-driven platform that connects psychiatrists with clinical aides and automated admin support. The funding was led by Headline, with mathias Schilling, its co-founder, joining the board. Village Global and TA Ventures, along with new supporters Operator Partners and Correlation Ventures, and angel investors from General Catalyst, Flatiron Health, Sword Health, and Zip, participated in the round.
Founded by CEO John Zhao, Blossom Health operates on the premise that time, not clinical knowledge, is the bottleneck in psychiatric care. U.S. psychiatrists dedicate around half of their work hours to non-clinical duties like documentation, billing, insurance authorization, and scheduling. Blossom’s platform employs a network of AI agents to manage these tasks, alongside clinical copilots who assist in symptom evaluation, diagnosis refinement, and medication selection.
The psychiatric workforce shortage in the U.S. is critical, with over 122 million Americans living in areas with insufficient mental health professionals, according to the Health Resources and Services Administration. The psychiatrist-to-population ratio is about one provider per 5,058 residents, and many psychiatrists are nearing retirement. Initial appointment wait times can extend from three weeks to six months, especially in rural areas with no psychiatrists.
This gap has led to a market for digital health startups in the U.S., which raised $14.2 billion in 2025. AI-powered companies comprised 54% of that funding. In the mental health sector, Talkiatry raised $210 million, and Spring Health, valued at $3.3 billion, uses AI for personalized treatment. AI-driven ambient clinical scribes generated $600 million in revenue last year.
Blossom claims its tools are utilized by hundreds of clinicians treating over 10,000 patients in multiple states. Many appointments are scheduled within 48 hours, often on the same day, and Blossom accepts major commercial insurers with average copays of about $22.
Blossom emphasizes a “copilot” model where AI tools assist but do not replace licensed psychiatrists, supporting them by surfacing information, evaluating symptoms, and suggesting medication adjustments. Between appointments, AI agents maintain patient contact via text check-ins, preparing information for clinicians.
While Blossom says it can stabilize mental health conditions and prevent the need for intensive care, it has not yet published peer-reviewed clinical evidence. Its data set of 10,000 patients is significant for a young company but insufficient for broad clinical conclusions.
In contrast to Cerebral, whose rapid growth sparked a DOJ investigation and a $7 million FTC settlement over questionable practices, Blossom uses a different approach. It works with licensed psychiatrists, and its AI is a support tool rather than a decision-maker. The challenge is to enhance psychiatric care volume through technology while maintaining clinical quality.
The $20 million funding will support expansion into more states, new insurance partnerships, clinician recruitment, and ongoing R&D. As a young company with significant operational achievements in network insurance coverage, the effectiveness of its clinical copilot in improving outcomes or streamlining care remains to be examined in the next funding round.